[go: up one dir, main page]

GB201702339D0 - Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines - Google Patents

Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines

Info

Publication number
GB201702339D0
GB201702339D0 GBGB1702339.1A GB201702339A GB201702339D0 GB 201702339 D0 GB201702339 D0 GB 201702339D0 GB 201702339 A GB201702339 A GB 201702339A GB 201702339 D0 GB201702339 D0 GB 201702339D0
Authority
GB
United Kingdom
Prior art keywords
immunocytokines
specific
antiboies
antibodies
specific immunocytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1702339.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB1702339.1A priority Critical patent/GB201702339D0/en
Publication of GB201702339D0 publication Critical patent/GB201702339D0/en
Priority to US16/311,421 priority patent/US20230192859A9/en
Priority to TW106120562A priority patent/TWI784957B/en
Priority to US16/311,434 priority patent/US11965026B2/en
Priority to BR112018076260-1A priority patent/BR112018076260A2/en
Priority to TW106120563A priority patent/TW201803905A/en
Priority to RU2018147413A priority patent/RU2756236C2/en
Priority to JP2019518159A priority patent/JP7461741B2/en
Priority to CN202310686837.5A priority patent/CN116903741A/en
Priority to EP17734406.6A priority patent/EP3471754A1/en
Priority to TW106120564A priority patent/TWI640536B/en
Priority to US16/311,440 priority patent/US20190330351A1/en
Priority to PCT/GB2017/051796 priority patent/WO2017220990A1/en
Priority to KR1020197001344A priority patent/KR102531889B1/en
Priority to EP17734405.8A priority patent/EP3471753A1/en
Priority to NZ789594A priority patent/NZ789594B2/en
Priority to CN201780045595.4A priority patent/CN109475602B/en
Priority to AU2017281830A priority patent/AU2017281830B2/en
Priority to TW107130649A priority patent/TWI793162B/en
Priority to MX2018016364A priority patent/MX2018016364A/en
Priority to PCT/GB2017/051794 priority patent/WO2017220988A1/en
Priority to CN201780045604.XA priority patent/CN109475603B/en
Priority to BR112018076281-4A priority patent/BR112018076281A2/en
Priority to CA3026474A priority patent/CA3026474A1/en
Priority to PCT/GB2017/051795 priority patent/WO2017220989A1/en
Priority to RU2018147423A priority patent/RU2769282C2/en
Priority to CA3026477A priority patent/CA3026477A1/en
Priority to IL263834A priority patent/IL263834B2/en
Priority to NZ748710A priority patent/NZ748710B2/en
Priority to KR1020197001346A priority patent/KR102379464B1/en
Priority to SG11201810509PA priority patent/SG11201810509PA/en
Priority to JP2019518160A priority patent/JP7261379B2/en
Priority to TW106126908A priority patent/TWI760352B/en
Priority to CN201780045638.9A priority patent/CN109689688B/en
Priority to RU2019104980A priority patent/RU2764548C2/en
Priority to CN202310348318.8A priority patent/CN117736325A/en
Priority to CN202310636091.7A priority patent/CN116640214A/en
Priority to CA3032897A priority patent/CA3032897A1/en
Priority to KR1020197006706A priority patent/KR102604433B1/en
Priority to BR112019002529-4A priority patent/BR112019002529A2/en
Priority to EP17752162.2A priority patent/EP3497128A2/en
Priority to PCT/GB2017/052352 priority patent/WO2018029474A2/en
Priority to JP2019529699A priority patent/JP7198752B2/en
Priority to KR1020237009918A priority patent/KR20230044038A/en
Priority to US16/323,980 priority patent/US11858996B2/en
Priority to US15/698,600 priority patent/US9957323B2/en
Priority to PCT/GB2017/053826 priority patent/WO2018115859A1/en
Priority to US16/471,161 priority patent/US20200190191A1/en
Priority to EP17840565.0A priority patent/EP3559041A1/en
Priority to JP2019533195A priority patent/JP7290568B2/en
Priority to ZA2019/00353A priority patent/ZA201900353B/en
Priority to US17/243,372 priority patent/US12209128B2/en
Priority to US17/727,309 priority patent/US20220403029A1/en
Priority to US17/727,288 priority patent/US20220380467A1/en
Priority to JP2022089801A priority patent/JP7448586B2/en
Priority to JP2022129085A priority patent/JP7595618B2/en
Priority to US17/901,800 priority patent/US20230312720A1/en
Priority to JP2022143907A priority patent/JP2022180438A/en
Priority to JP2023016174A priority patent/JP7750887B2/en
Priority to US18/499,431 priority patent/US20240158502A1/en
Priority to JP2023205810A priority patent/JP7781129B2/en
Priority to US18/592,425 priority patent/US20240360218A1/en
Priority to US18/616,452 priority patent/US20240343810A1/en
Priority to JP2024133793A priority patent/JP2024167230A/en
Priority to JP2025157613A priority patent/JP2026001069A/en
Ceased legal-status Critical Current

Links

GBGB1702339.1A 2016-06-20 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines Ceased GB201702339D0 (en)

Priority Applications (65)

Application Number Priority Date Filing Date Title
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines
US16/311,421 US20230192859A9 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
TW106120562A TWI784957B (en) 2016-06-20 2017-06-20 Immunocytokines
US16/311,434 US11965026B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 cytokines
BR112018076260-1A BR112018076260A2 (en) 2016-06-20 2017-06-20 antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
TW106120563A TW201803905A (en) 2016-06-20 2017-06-20 Multiple specific antibody for immunooncology
RU2018147413A RU2756236C2 (en) 2016-06-20 2017-06-20 Pd-l1 specific antibodies
JP2019518159A JP7461741B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 Cytokines
CN202310686837.5A CN116903741A (en) 2016-06-20 2017-06-20 Antibodies or antigen binding fragments thereof that specifically bind to PD-L1 and uses thereof
EP17734406.6A EP3471754A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
TW106120564A TWI640536B (en) 2016-06-20 2017-06-20 antibody
US16/311,440 US20190330351A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
PCT/GB2017/051796 WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
KR1020197001344A KR102531889B1 (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 cytokines
EP17734405.8A EP3471753A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
NZ789594A NZ789594B2 (en) 2017-06-20 Anti-PD-L1 antibodies
CN201780045595.4A CN109475602B (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 cytokines
AU2017281830A AU2017281830B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 antibodies
TW107130649A TWI793162B (en) 2016-06-20 2017-06-20 Antibodies
MX2018016364A MX2018016364A (en) 2016-06-20 2017-06-20 ANTI-PD-L1 ANTIBODIES.
PCT/GB2017/051794 WO2017220988A1 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
CN201780045604.XA CN109475603B (en) 2016-06-20 2017-06-20 Anti-PD-L1 antibody
BR112018076281-4A BR112018076281A2 (en) 2016-06-20 2017-06-20 immunocytocin, use of an immunocytocin, method, pharmaceutical composition, method for treating a proliferative disease in an animal, nucleic acid, vector, host and antibody or fragment thereof
CA3026474A CA3026474A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
PCT/GB2017/051795 WO2017220989A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
RU2018147423A RU2769282C2 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
CA3026477A CA3026477A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
IL263834A IL263834B2 (en) 2016-06-20 2017-06-20 Antibodies against PD-L1
NZ748710A NZ748710B2 (en) 2017-06-20 Anti-pd-l1 antibodies
KR1020197001346A KR102379464B1 (en) 2016-06-20 2017-06-20 anti-PD-L1 antibody
SG11201810509PA SG11201810509PA (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
JP2019518160A JP7261379B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 antibody
TW106126908A TWI760352B (en) 2016-08-09 2017-08-09 Anti-icos antibodies
CN201780045638.9A CN109689688B (en) 2016-08-09 2017-08-09 anti-ICOS antibody
RU2019104980A RU2764548C2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
CN202310348318.8A CN117736325A (en) 2016-08-09 2017-08-09 Isolated antibodies and uses thereof
CN202310636091.7A CN116640214A (en) 2016-08-09 2017-08-09 Isolating Antibodies and Their Applications
CA3032897A CA3032897A1 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
KR1020197006706A KR102604433B1 (en) 2016-08-09 2017-08-09 anti-ICOS antibodies
BR112019002529-4A BR112019002529A2 (en) 2016-08-09 2017-08-09 isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
EP17752162.2A EP3497128A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
PCT/GB2017/052352 WO2018029474A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
JP2019529699A JP7198752B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibody
KR1020237009918A KR20230044038A (en) 2016-08-09 2017-08-09 Anti-icos antibodies
US16/323,980 US11858996B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibodies
US15/698,600 US9957323B2 (en) 2016-06-20 2017-09-07 Anti-ICOS antibodies
PCT/GB2017/053826 WO2018115859A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
US16/471,161 US20200190191A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
EP17840565.0A EP3559041A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
JP2019533195A JP7290568B2 (en) 2016-12-20 2017-12-19 Multispecific antibodies in combination therapy for cancer immunotherapy
ZA2019/00353A ZA201900353B (en) 2016-06-20 2019-01-17 Anti-pd-l1 antibodies
US17/243,372 US12209128B2 (en) 2016-06-20 2021-04-28 Anti-PD-L1 antibodies
US17/727,309 US20220403029A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
US17/727,288 US20220380467A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
JP2022089801A JP7448586B2 (en) 2016-08-09 2022-06-01 Anti-ICOS antibody
JP2022129085A JP7595618B2 (en) 2016-06-20 2022-08-12 Anti-PD-L1 antibody
US17/901,800 US20230312720A1 (en) 2016-06-20 2022-09-01 Multispecific antibodies for immuno-oncology
JP2022143907A JP2022180438A (en) 2016-06-20 2022-09-09 Anti-PD-L1 and IL-2 cytokines
JP2023016174A JP7750887B2 (en) 2016-12-20 2023-02-06 Multispecific antibodies in combination therapy for cancer immunotherapy
US18/499,431 US20240158502A1 (en) 2016-08-09 2023-11-01 Anti-icos antibodies
JP2023205810A JP7781129B2 (en) 2016-08-09 2023-12-06 Anti-ICOS antibody
US18/592,425 US20240360218A1 (en) 2016-06-20 2024-02-29 Anti-pd-l1 and il-2 cytokines
US18/616,452 US20240343810A1 (en) 2016-06-20 2024-03-26 Multispecific antibodies for immuno-oncology
JP2024133793A JP2024167230A (en) 2016-06-20 2024-08-09 Anti-PD-L1 antibody
JP2025157613A JP2026001069A (en) 2016-12-20 2025-09-24 Multispecific antibodies in combination therapy for cancer immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines

Publications (1)

Publication Number Publication Date
GB201702339D0 true GB201702339D0 (en) 2017-03-29

Family

ID=58462057

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1702339.1A Ceased GB201702339D0 (en) 2016-06-20 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines

Country Status (1)

Country Link
GB (1) GB201702339D0 (en)

Similar Documents

Publication Publication Date Title
IL312910B1 (en) Anti-galectin-9 antibodies and uses thereof
ZA202105676B (en) Anti-trem2 antibodies and related methods
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL272218A (en) Anti-sirp-alpha antibodies and related methods
IL268734A (en) Anti-lag-3 antibodies and uses thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL275577A (en) Antibodies and variants thereof against pd-l1
IL273157A (en) Axl-specific antibodies and uses thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL281297B1 (en) Anti-npr1 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL274202A (en) Anti-glyco-muc1 antibodies and their uses
IL277330A (en) Anti-il-27 antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof
GB201702338D0 (en) Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)